Our team of experienced Business Development experts are assisting the CEO of Orion Biotechnology with a 10m USD funding round.
Orion Biotechnology is discovering and developing G Protein-Coupled Receptor (GPCR) targeted therapies to treat metabolic and immunological diseases
Our team of experienced Business Development experts are assisting the CEO of Omnispirant Therapeutics with an 80m Euros funding round.
OmniSpirant Limited was founded by Gerry McCauley in 2016. Gerry qualified as a Master of Pharmacy in 2001. Gerry has extensive commercial knowledge, industry contacts and has built an international network of experts in the fields of cell and gene therapy and respiratory drug delivery. Gerry is the inventor of OmniSpirant’s patent pending inhaled exosome technology.
Our team of experienced Business Development experts are assisting the Founder of Telexos with an undisclosed funding round.
Telexos develops products for the clinical cancer research market and for the personalized cancer diagnostics market. Focus of the developments is the detection and analysis of rare cells in blood, in particular circulating tumor cells (CTCs) and rare immune cells. Telexos started its laboratory in mid 2019.
Our team of experienced Business Development experts are assisting the President of Radiatric with an undisclosed funding round.
Radiatric is a medical device company. We are currently developing a device to treat patients that have bloodborne infections that could lead to sepsis. Sepsis is a life-threatening infection caused by bacteria that have entered the blood. Our device treats infections caused by bacteria in the bloodstream without the use of antibiotics. There is a significant need to develop new treatment methods as bacteria continue to develop resistance to antibiotics. It is unlikely bacteria would be able to develop resistance to the Radiatric RAD-01 device due to its unique method of action.
Our team of experienced Business Development experts are assisting the CEO of NUAgo Therapeutics with an undisclosed funding round.
NUAgo Therapeutics is redefining the precision approach in cancer therapeutics. We are a pre-clinical stage company developing single-construct short RNAs that target dozens of critical cancer essential genes in systemic delivery platform that kill tumors specifically without observed toxicity in normal tissues.
No longer bound to the treatment restrictions imposed due to patient and tumor heterogeneity, NUAgo's short RNAs offer the promise shift to potentially shift cancer therapy toward a chronic-like condition with periods of complete response or tumor elimination.
Our team of experienced Business Development experts are assisting the CEO of ReGelTec with an undisclosed funding round.
ReGelTec, Inc. is a clinical stage medical device company that focuses on developing the next generation of interventional spinal implants. Their mission is to address chronic lower back pain caused by degenerative disc disease.
Our team of experienced Business Development experts are assisting the CEO of Pleco Therapeutics with an undisclosed funding round.
Pleco Therapeutics aims to extend the life span and enhance the quality of life of patients through its novel Plecoid™ therapies that dramatically increase the effectiveness of current cancer treatments.
Copyright © 2024 DON Therapeutics - All Rights Reserved.
DON THERAPEUTICS LTD is not a Registered Investment Advisor, Broker/Dealer, Financial Analyst, Financial Bank, Securities Broker or Financial Planner. The Information on this 1. Company email, 2 Company Site, 3 Company LinkedIn is provided for information purposes only. The Information is not intended to be and does not constitute financial advice or any other advice, is general in nature and not specific to you. Before using the Company’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence. None of the information on our email, website, or LinkedIn is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. The Company is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.
Powered by DON Therapeutics